WEIGHT LOSS TREATMENTS

Mounjaro targets both the GLP-1 and GIP receptors, meaning that as well as slowing stomach emptying and increasing fullness and satiety, it plays an additional role in enhancing the body's ability to use stored fat as energy, and potentially providing broader weight management effects.

• Mounjaro is taken as a once-weekly, dose-set pen injection.

A trial with 2539 adults found that weekly tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks achieved significant weight loss in overweight and obese patients, with a higher percentage achieving 5%, 10%, 15%, and 20% or more weight loss compared to placebo.¹

Should be combined with healthy lifestyle interventions for better outcomes.

• Nausea

• Diarrhoea

• Vomiting

• Pancreatitis (rarely)

*If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.

Semaglutide may be better known under its brand names Ozempic and Wegovy. Both Ozempic and Wegovy are once-weekly injectable medications licensed for the treatment of type-2 diabetes. Recently, Wegovy has been approved for weight loss. Semaglutide works by targeting the GLP-1 receptor, slowing stomach emptying, increasing fullness, and reducing cravings. Semaglutide has been shown to reduce certain cardiovascular events by up to 20%.⁶

• Semaglutide is taken as a once-weekly, dose-set pen injection.

In a study with 1961 adults, semaglutide (2.4 mg) over 68 weeks resulted in a 15% weight reduction, with 86% of adults achieving significant weight loss.⁷

Should be combined with a reduced-calorie diet and exercise

• Nausea

• Diarrhoea

• Vomiting

• Pancreatitis (rarely)

*If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.

Saxenda was the first approved GLP-1 receptor agonist for weight management, administered as a once-daily injection. It works in the hypothalamus, where it promotes signals that help to regulate appetite and food intake.

• Saxenda is taken daily.

Liraglutide significantly outperformed placebo in weight loss among obese/overweight patients, with more patients achieving ≥ 5% and >10% weight loss with Liraglutide than with placebo. In a 160-week trial, weight loss mainly occurred in the first year and was sustained. Early responders, defined as those losing ≥ 5% weight in the first 12 weeks, saw continued benefits: 86.2% achieved ≥ 5% and 51% reached ≥ 10% weight loss after one year, averaging an 11.2% reduction in baseline body weight.⁸

• Should be combined with a reduced-calorie diet and exercise

• Nausea

• Diarrhoea

• Vomiting

• Pancreatitis (rarely)

*If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.

The active ingredient in Alli, orlistat, works by decreasing the amount of dietary fat your body can absorb by blocking the action of lipase, the enzyme responsible for breaking down fats to be absorbed by the intestines. This means that around a quarter of the fat you eat while taking Alli won’t be broken down, and is instead passed through the body.

• Taken as an oral capsule, three times per day with fat-containing meals.

In the 4-year XENDOS trial, 60% of patients on orlistat and 35% on placebo lost at least 5% of their baseline body weight after 12 weeks. Of these, 62% of orlistat patients and 52% of placebo patients lost ≥ 10% of their baseline weight after one year. Only 5% of orlistat and 4% of placebo patients who did not lose 5% initially reached a 10% weight loss after one year.⁹

• It’s recommended that you keep your fat intake to no more than 30% of your total calories, or about 15 grams of fat per meal

• Side effects can be unpleasant

• Frequent bowel movements

• Faecal incontinence

• Abdominal pain

• Diarrhoea

  *If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.

Mysimba (naltrexone-bupropion) is a medication used for long-term management of obesity, along with exercise and a reduced-calorie diet. Naltrexone works by affecting certain neurons in the brain, while bupropion increases dopamine activity. Together, they help reduce food cravings.¹⁰

• One tablet for seven days, then one tablet twice daily for seven days, then three tablets daily for seven days, then two tablets twice daily.

In the Phase 3 studies with 4,536 participants, those treated with naltrexone/bupropion experienced a mean body weight loss of 5.4%, compared to 1.3% in the placebo group. Additionally, 31% of patients on naltrexone/bupropion achieved at least a 5% reduction in baseline body weight, versus 12% on placebo.¹⁰

• Significant side effect profile

• Needs to be weaned off if stopping

• Shouldn’t be used in those with underlying mental health conditions

• Dizziness

• Headaches

• Abdominal pain

• Insomnia

• Tremors

*If you are prescribed this medication please read the patient information leaflet provided with the product for a full list of side effects. If you are concerned about any of this medication’s side effects, please contact one of our Numan clinicians or your local GP.